Lars Weidolf

3.8k total citations · 1 hit paper
61 papers, 3.1k citations indexed

About

Lars Weidolf is a scholar working on Pharmacology, Molecular Biology and Spectroscopy. According to data from OpenAlex, Lars Weidolf has authored 61 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pharmacology, 15 papers in Molecular Biology and 15 papers in Spectroscopy. Recurrent topics in Lars Weidolf's work include Pharmacogenetics and Drug Metabolism (29 papers), Analytical Chemistry and Chromatography (12 papers) and Drug Transport and Resistance Mechanisms (12 papers). Lars Weidolf is often cited by papers focused on Pharmacogenetics and Drug Metabolism (29 papers), Analytical Chemistry and Chromatography (12 papers) and Drug Transport and Resistance Mechanisms (12 papers). Lars Weidolf collaborates with scholars based in Sweden, United Kingdom and United States. Lars Weidolf's co-authors include Tommy B. Andersson, Ulrik Jurva, Xueqing Li, Tommy Andersson, Emre M. Isin, Jack D. Henion, Andries P. Bruins, Richard A. Thompson, Tove Johansson and Madeleine Antonsson and has published in prestigious journals such as Gastroenterology, Analytical Chemistry and Journal of Medicinal Chemistry.

In The Last Decade

Lars Weidolf

59 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

2004 495 citations Xueqing Li, Tommy B. Andersson et al. Drug Metabolism and Disposition profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Weidolf Sweden	28	923	725	587	399	381	61	3.1k
Inger Skånberg Sweden	27	576 0.6×	541 0.7×	273 0.5×	513 1.3×	403 1.1×	168	2.8k
Anna‐Lena Ungell Sweden	32	628 0.7×	863 1.2×	348 0.6×	1.7k 4.2×	310 0.8×	57	3.9k
Fakhreddin Jamali Canada	35	1.2k 1.3×	687 0.9×	998 1.7×	681 1.7×	298 0.8×	124	4.1k
Thomas N. Tozer United States	30	499 0.5×	717 1.0×	217 0.4×	475 1.2×	154 0.4×	71	3.2k
Neil Parrott Switzerland	37	1.5k 1.6×	1.0k 1.4×	578 1.0×	1.3k 3.2×	151 0.4×	125	4.5k
Xiaoyan Chen China	35	801 0.9×	1.4k 1.9×	551 0.9×	693 1.7×	227 0.6×	222	4.4k
Karl Zech Germany	30	475 0.5×	636 0.9×	289 0.5×	345 0.9×	242 0.6×	100	2.5k
Donglu Zhang United States	35	1.2k 1.3×	1.4k 2.0×	459 0.8×	957 2.4×	232 0.6×	122	5.0k
Shoji Awazu Japan	30	654 0.7×	969 1.3×	180 0.3×	839 2.1×	169 0.4×	184	3.0k
C G Regårdh Sweden	28	798 0.9×	438 0.6×	171 0.3×	776 1.9×	307 0.8×	59	2.8k

Countries citing papers authored by Lars Weidolf

Since Specialization

Citations

This map shows the geographic impact of Lars Weidolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Weidolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Weidolf more than expected).

Fields of papers citing papers by Lars Weidolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Weidolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Weidolf. The network helps show where Lars Weidolf may publish in the future.

Co-authorship network of co-authors of Lars Weidolf

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Weidolf. A scholar is included among the top collaborators of Lars Weidolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Weidolf. Lars Weidolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weidolf, Lars & Ian D. Wilson. (2023). Minimizing the DILI potential of carboxylic acid-containing drugs: a perspective. Medicinal Chemistry Research. 32(9). 2034–2047. 3 indexed citations

Jurva, Ulrik, Lars Weidolf, Anja Ekdahl, et al.. (2023). Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans. Drug Metabolism and Disposition. 51(4). 464–479. 6 indexed citations

Li, Xueqing, Marie Elebring, Anders Dahlén, & Lars Weidolf. (2023). In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans. Drug Metabolism and Disposition. 51(10). 1350–1361. 10 indexed citations

Weidolf, Lars, Anders Björkbom, Anders Dahlén, et al.. (2021). Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates. Drug Discovery Today. 26(10). 2244–2258. 20 indexed citations

Weidolf, Lars, Thomas Andersson, Joel P. Bercu, et al.. (2019). Qualification of impurities based on metabolite data. Regulatory Toxicology and Pharmacology. 110. 104524–104524. 12 indexed citations

Andersson, Shalini, Madeleine Antonsson, Marie Elebring, Rasmus Jansson‐Löfmark, & Lars Weidolf. (2018). Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Drug Discovery Today. 23(10). 1733–1745. 46 indexed citations

Svensson, Peder, et al.. (2017). Oxetane Substrates of Human Microsomal Epoxide Hydrolase. Drug Metabolism and Disposition. 45(8). 966–973. 13 indexed citations

Ekdahl, Anja, et al.. (2014). Systemic Exposure to the Metabolites of Lesogaberan in Humans and Animals: A Case Study of Metabolites in Safety Testing. Drug Metabolism and Disposition. 42(6). 1016–1021. 8 indexed citations

Samuelsson, Kristin, Kathryn Pickup, Sunil Sarda, et al.. (2014). Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice. Xenobiotica. 44(2). 186–195. 11 indexed citations

10.

Weidolf, Lars, et al.. (2010). P450‐catalyzed vs. electrochemical oxidation of haloperidol studied by ultra‐performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry. 24(9). 1231–1240. 27 indexed citations

11.

Johansson, Tove, et al.. (2009). In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange. Drug Metabolism and Disposition. 38(1). 73–83. 63 indexed citations

12.

Afzelius, Lovisa, Catrin Hasselgren Arnby, Anders Broo, et al.. (2007). State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications. Drug Metabolism Reviews. 39(1). 61–86. 88 indexed citations

13.

Li, Xueqing, et al.. (2004). COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES. Drug Metabolism and Disposition. 32(8). 821–827. 495 indexed citations breakdown →

14.

Jensen, Berit Packert, Christopher J. Smith, Ian D. Wilson, & Lars Weidolf. (2003). Sensitive sulphur‐specific detection of omeprazole metabolites in rat urine by high‐performance liquid chromatography/inductively coupled plasma mass spectrometry. Rapid Communications in Mass Spectrometry. 18(2). 181–183. 29 indexed citations

15.

Jurva, Ulrik, Håkan Wikström, Lars Weidolf, & Andries P. Bruins. (2003). Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions. Rapid Communications in Mass Spectrometry. 17(8). 800–810. 178 indexed citations

16.

Andersson, Tommy, et al.. (2001). Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole. Clinical Pharmacokinetics. 40(6). 411–426. 196 indexed citations

17.

Weidolf, Lars & Neal Castagnoli. (2001). Study of the electrospray ionization mass spectrometry of the proton pump inhibiting drug Omeprazole. Rapid Communications in Mass Spectrometry. 15(4). 283–290. 15 indexed citations

18.

Backlund, Maria, Lars Weidolf, & Magnus Ingelman‐Sundberg. (1999). Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells. European Journal of Biochemistry. 261(1). 66–71. 35 indexed citations

19.

Weidolf, Lars, Kurt Karlsson, & I. M. Nilsson. (1992). A metabolic route of omeprazole involving conjugation with glutathione identified in the rat.. Drug Metabolism and Disposition. 20(2). 262–267. 15 indexed citations

20.

Weidolf, Lars, et al.. (1988). ボルデノン・ウンデシレン酸塩(エキポイズ TM )投与後のウマ尿中のボルデノン硫酸塩のスクリーニング,確認および定量. Journal of Chromatography A. 433. 9–21. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact